News
PCRX
29.22
+0.62%
0.18
Weekly Report: what happened at PCRX last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at PCRX last week (0311-0315)?
Weekly Report · 03/18 09:11
Analysts Expect IJR Will Reach $120
NASDAQ · 03/14 11:15
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
Pacira BioSciences has won a key U.S. Food and Drug Administration designation for its gene-therapy product candidate for osteoarthritis of the knee. The FDA's first-ever RMAT designation for a product candidate in osteo arthritis. The company says the designation is supported by encouraging preliminary data.
Dow Jones · 03/13 11:41
Independent Director Of Pacira BioSciences Sold 85% Of Their Shares
Independent Director Gary Pace sold US$3.7m worth of Pacira BioSciences, Inc. Shares recently. The sale is the biggest single sale by an insider of the company in the last year. The insider sale amounts to 85% of the firm's share price. Pacira biosciences insiders didn't buy any shares over the last 12 months. The company has a high insider ownership of 1.2% of its shares. You can see the insider transactions at Pacira Biosecences   .
Simply Wall St · 03/11 10:47
Weekly Report: what happened at PCRX last week (0304-0308)?
Weekly Report · 03/11 09:11
Teva upgraded at J.P. Morgan on upcoming catalysts
J.P. Morgan reviewed its specialty pharma coverage and upgraded generic drugmaker Teva to Neutral from Underweight. Analyst cited a favorable catalyst set up in the months ahead for the company. Teva Pharmaceutical stock traded higher on Friday after the upgrade. J.p. Morgan on upcoming catalysts for Teva.
Seeking Alpha · 03/08 15:21
Pacira BioSciences Price Target Announced at $45.00/Share by JP Morgan
Dow Jones · 03/07 10:17
Pacira BioSciences Coverage Assumed by JP Morgan at Overweight
Dow Jones · 03/07 10:17
JP Morgan Assumes Pacira BioSciences at Overweight, Announces Price Target of $45
Benzinga · 03/07 10:07
HC Wainwright & Co. Reiterates Buy on Pacira BioSciences, Maintains $57 Price Target
Benzinga · 03/04 12:02
Buy Rating for Pacira Pharmaceuticals Amid Strong Growth Prospects and Robust IP Protection
TipRanks · 03/04 11:27
Weekly Report: what happened at PCRX last week (0226-0301)?
Weekly Report · 03/04 09:11
Buy Rating Affirmed for Pacira Pharmaceuticals Amid Strategic Growth Initiatives and Management Restructuring
Analyst Balaji Prasad of Barclays maintained a Buy rating on Pacira Pharmaceuticals (PCRX) with a price target of $40.00. The company is in a transition year and is preparing for the launch of Exparel for lower extremity nerve blocks. The restructuring within the company is expected to drive long-term growth.
TipRanks · 03/03 15:15
Navigating 4 Analyst Ratings For Pacira BioSciences
Pacira BioSciences is a provider of non-opioid pain management and regenerative health solutions. The company has an average 12-month price target of $47.25. Four analysts have shared their insights on Pacira Biosciences over the past three months. The average price target has been decreased by 10.85%. The company's revenue growth lags behind its peers in the Health Care sector.
Benzinga · 03/01 16:00
Pacira BioSciences Is Maintained at Outperform by RBC Capital
Dow Jones · 03/01 15:49
Pacira BioSciences Price Target Cut to $45.00/Share From $53.00 by RBC Capital
Dow Jones · 03/01 15:49
RBC Capital Maintains Outperform on Pacira BioSciences, Lowers Price Target to $45
Benzinga · 03/01 15:35
Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT) and Pacira Pharmaceuticals (PCRX)
TipRanks · 03/01 14:30
Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations
Pacira BioSciences reported a 12% rise in revenue to US$675.0m. The company's shares are down 1.1% from a week ago. Revenue was in line with analyst estimates. Earnings per share surpassed analyst estimates by 12%. Revenue is forecast to grow 8.1%.
Simply Wall St · 03/01 13:17
More
Webull provides a variety of real-time PCRX stock news. You can receive the latest news about Pacira Biosciences Inc through multiple platforms. This information may help you make smarter investment decisions.
About PCRX
Pacira BioSciences, Inc. is a holding company for Pacira Pharmaceuticals, Inc. The Company's non-opioid treatments include EXPAREL (bupivacaine liposome injectable suspension), which is a long-acting, local analgesic for postsurgical pain management; ZILRETTA (triamcinolone acetonide extended-release injectable suspension), which is an extended-release, intra-articular (IA), corticosteroid injection indicated for OA knee pain, and Iovera, which is a novel handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. EXPAREL is used across multiple orthopedic procedures, including joint reconstruction, shoulder, spine, extremity procedures, and hip fractures. It is developing interventions to address debilitating conditions involving the sympathetic nervous system, such as cardiac electrical storm, chronic pain. Its clinical development programs include PCRX-201, and pMVL-Based Clinical Program.